CoChat

A model of the onset of the senescence associated secretory phenotype after DNA damage induced senescence

Open access
Meyer, Patrick, Maity, Pallab, Burkovski, Andre, Schwab, Julian, Müssel, Christoph, Singh, Karmveer, Ferreira, Filipa F., Krug, Linda, Maier, Harald J., Wlaschek, Meinhard, Wirth, Thomas, Kestler, Hans A., Scharffetter-Kochanek, Karin · 2017 · PLOS Computational Biology
Cited by 75

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Cells and tissues are exposed to stress from numerous sources. Senescence is a protective mechanism that prevents malignant tissue changes and constitutes a fundamental mechanism of aging. It can be accompanied by a senescence associated secretory phenotype (SASP) that causes chronic inflammation. We present a Boolean network model-based gene regulatory network of the SASP, incorporating published gene interaction data. The simulation results describe current biological knowledge. The model predicts different in-silico knockouts that prevent key SASP-mediators, IL-6 and IL-8, from getting activated upon DNA damage. The NF-κB Essential Modulator (NEMO) was the most promising in-silico knockout candidate and we were able to show its importance in the inhibition of IL-6 and IL-8 following DNA-damage in murine dermal fibroblasts in-vitro. We strengthen the speculated regulator function of the NF-κB signaling pathway in the onset and maintenance of the SASP using in-silico and in-vitro approaches. We were able to mechanistically show, that DNA damage mediated SASP triggering of IL-6 and IL-8 is mainly relayed through NF-κB, giving access to possible therapy targets for SASP-accompanied diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pcbi.1005741

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 98

  1. DP Goldman, 2013, Substantial health and economic returns from delayed aging may warrant a new focus for medical research, Health Aff (Millwood), 32, 1698, 10.1377/hlthaff.2013.0052 · DOI · Paper page
  2. HA Kestler, 2008, Network modeling of signal transduction: establishing the global view, Bioessays, 30, 1110, 10.1002/bies.20834 · DOI · Paper page
  3. A Naldi, 2015, Cooperative development of logical modelling standards and tools with CoLoMoTo, Bioinformatics, 31, 1154, 10.1093/bioinformatics/btv013 · DOI
  4. I Shmulevich, 2007, Genomic Signal Processing, 10.1515/9781400865260 · doi:10.1515/9781400865260
  5. H de Jong, 2002, Modeling and simulation of genetic regulatory systems: a literature review, J Comput Biol, 9, 67, 10.1089/10665270252833208 · DOI · Paper page
  6. S Kauffman, 1969, Homeostasis and differentiation in random genetic control networks, Nature, 224, 177, 10.1038/224177a0 · DOI · Paper page
  7. N Le Novere, 2015, Quantitative and logic modelling of molecular and gene networks, Nat Rev Genet, 16, 146, 10.1038/nrg3885 · DOI · Paper page
  8. J Fisher, 2007, Executable cell biology, Nature biotechnology, 25, 1239, 10.1038/nbt1356 · DOI · Paper page
  9. Harvey I, Bossomaier T. Time Out of Joint: Attractors in Asynchronous Ramdom Boolean Networks. In: Husbands P, Harvey I, editors. Proceedings of the Fourth European Artificial Life Conference: MIT Press; 1997. p. 67–75.
  10. Klarner H, Bockmayr A, Siebert H. Computing Symbolic Steady States of Boolean Networks. In: Wąs J, Sirakoulis GC, Bandini S, editors. Cellular Automata: 11th International Conference on Cellular Automata for Research and Industry, ACRI 2014, Krakow, Poland, September 22–25, 2014 Proceedings. Cham: Springer International Publishing; 2014. p. 561–70. · doi:10.1007/978-3-319-11520-7_59
  11. JGT Zañudo, 2013, An effective network reduction approach to find the dynamical repertoire of discrete dynamic networks, Chaos: An Interdisciplinary Journal of Nonlinear Science, 23, 025111, 10.1063/1.4809777 · DOI
  12. M Dahlhaus, 2016, Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma, Cancer letters, 371, 79, 10.1016/j.canlet.2015.11.025 · DOI
  13. D MacLean, 2010, A Boolean model of the Pseudomonas syringae hrp regulon predicts a tightly regulated system, PloS one, 5, e9101, 10.1371/journal.pone.0009101 · DOI
  14. F Herrmann, 2012, A boolean model of the cardiac gene regulatory network determining first and second heart field identity, PloS one, 7, e46798, 10.1371/journal.pone.0046798 · DOI · Paper page
  15. HA Kestler, 2008, From individual Wnt pathways towards a Wnt signalling network, Philosophical transactions of the Royal Society of London Series B, Biological sciences, 363, 1333, 10.1098/rstb.2007.2251 · DOI · Paper page
  16. AM Feist, 2009, Reconstruction of biochemical networks in microorganisms, Nat Rev Microbiol, 7, 129, 10.1038/nrmicro1949 · DOI · Paper page
  17. A Saadatpour, 2013, A Reduction Method for Boolean Network Models Proven to Conserve Attractors, SIAM Journal on Applied Dynamical Systems, 12, 1997, 10.1137/13090537X · DOI
  18. A Veliz-Cuba, 2011, Reduction of Boolean network models, Journal of theoretical biology, 289, 167, 10.1016/j.jtbi.2011.08.042 · DOI
  19. J Hiscott, 1993, Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop, Molecular and cellular biology, 13, 6231, 10.1128/MCB.13.10.6231 · DOI · Paper page
  20. N Mori, 1996, Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins, Blood, 87, 3410, 10.1182/blood.V87.8.3410.bloodjournal8783410 · DOI · Paper page
  21. H Holtmann, 1999, Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways, Molecular and cellular biology, 19, 6742, 10.1128/MCB.19.10.6742 · DOI · Paper page
  22. TA Libermann, 1990, Activation of interleukin-6 gene expression through the NF-kappa B transcription factor, Molecular and cellular biology, 10, 2327, 10.1128/MCB.10.5.2327 · doi:10.1128/mcb.10.5.2327 · Paper page
  23. YH Son, 2008, Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells, Journal of cardiovascular pharmacology, 51, 71, 10.1097/FJC.0b013e31815bd23d · DOI · Paper page
  24. GY Park, 2001, Anti-inflammatory effect of adenovirus-mediated IkappaBalpha overexpression in respiratory epithelial cells, The European respiratory journal, 18, 801, 10.1183/09031936.01.00099801 · doi:10.1183/09031936.01.00099801
  25. M Schmidt-Supprian, 2000, NEMO/IKK gamma-deficient mice model incontinentia pigmenti, Molecular cell, 5, 981, 10.1016/S1097-2765(00)80263-4 · DOI · Paper page
  26. A Salminen, 2008, NEMO shuttle: a link between DNA damage and NF-kappaB activation in progeroid syndromes?, Biochemical and biophysical research communications, 367, 715, 10.1016/j.bbrc.2007.11.189 · DOI
  27. U Zurgil, 2014, PKCeta promotes senescence induced by oxidative stress and chemotherapy, Cell death & disease, 5, e1531, 10.1038/cddis.2014.481 · DOI
  28. H Sebban, 2006, Posttranslational modifications of NEMO and its partners in NF-kappaB signaling, Trends Cell Biol, 16, 569, 10.1016/j.tcb.2006.09.004 · DOI
  29. A Israel, 2010, The IKK complex, a central regulator of NF-kappaB activation, Cold Spring Harbor perspectives in biology, 2, a000158, 10.1101/cshperspect.a000158 · DOI · Paper page
  30. GE Holmes, 1992, Oxidative and other DNA damages as the basis of aging: a review, Mutat Res, 275, 305, 10.1016/0921-8734(92)90034-M · DOI
  31. A Badache, 2001, Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells, Cancer research, 61, 383
  32. JP Coppe, 2010, The senescence-associated secretory phenotype: the dark side of tumor suppression, Annu Rev Pathol, 5, 99, 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
  33. JK Lee, 2012, Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study, PloS one, 7, e34218, 10.1371/journal.pone.0034218 · DOI · Paper page
  34. G Habineza Ndikuyeze, 2014, A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma, PloS one, 9, e95404, 10.1371/journal.pone.0095404 · DOI · Paper page
  35. S Dai, 2004, The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis, The Journal of biological chemistry, 279, 37219, 10.1074/jbc.C400258200 · DOI · Paper page
  36. B Zheng, 2002, Ligand-dependent genetic recombination in fibroblasts: a potentially powerful technique for investigating gene function in fibrosis, The American journal of pathology, 160, 1609, 10.1016/S0002-9440(10)61108-X · DOI · Paper page
  37. H Wang, 2014, Improved seamless mutagenesis by recombineering using ccdB for counterselection, Nucleic acids research, 42, e37, 10.1093/nar/gkt1339 · DOI
  38. K Singh, 2015, Superoxide anion radicals induce IGF-1 resistance through concomitant activation of PTP1B and PTEN, EMBO Mol Med, 7, 59, 10.15252/emmm.201404082 · DOI · Paper page
  39. JG Zañudo, 2015, Cell fate reprogramming by control of intracellular network dynamics, PLoS computational biology, 11, e1004193, 10.1371/journal.pcbi.1004193 · DOI · Paper page
  40. C Müssel, 2010, BoolNet—an R package for generation, reconstruction and analysis of Boolean networks, Bioinformatics, 26, 1378, 10.1093/bioinformatics/btq124 · DOI · Paper page
  41. J Smith, 2010, The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer, Advances in cancer research, 108, 73, 10.1016/B978-0-12-380888-2.00003-0 · DOI · Paper page
  42. Q Zhan, 1996, Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation, DNA and cell biology, 15, 805, 10.1089/dna.1996.15.805 · DOI · Paper page
  43. E Appella, 2001, Post-translational modifications and activation of p53 by genotoxic stresses, European journal of biochemistry / FEBS, 268, 2764, 10.1046/j.1432-1327.2001.02225.x · DOI · Paper page
  44. A Hirao, 2000, DNA damage-induced activation of p53 by the checkpoint kinase Chk2, Science, 287, 1824, 10.1126/science.287.5459.1824 · DOI · Paper page
  45. Q Ke, 2006, Hypoxia-inducible factor-1 (HIF-1), Molecular pharmacology, 70, 1469, 10.1124/mol.106.027029 · DOI · Paper page
  46. MV Blagosklonny, 1998, p53 inhibits hypoxia-inducible factor-stimulated transcription, The Journal of biological chemistry, 273, 11995, 10.1074/jbc.273.20.11995 · DOI · Paper page
  47. Y Xiong, 1993, p21 is a universal inhibitor of cyclin kinases, Nature, 366, 701, 10.1038/366701a0 · DOI · Paper page
  48. S Herold, 2002, Negative regulation of the mammalian UV response by Myc through association with Miz-1, Molecular cell, 10, 509, 10.1016/S1097-2765(02)00633-0 · DOI · Paper page
  49. J Brugarolas, 1999, Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation, Proceedings of the National Academy of Sciences of the United States of America, 96, 1002, 10.1073/pnas.96.3.1002 · DOI · Paper page
  50. RH Grafstrom, 1999, Defining the substrate specificity of cdk4 kinase-cyclin D1 complex, Carcinogenesis, 20, 193, 10.1093/carcin/20.2.193 · DOI
  51. RA Weinberg, 1995, The retinoblastoma protein and cell cycle control, Cell, 81, 323, 10.1016/0092-8674(95)90385-2 · DOI · Paper page
  52. UM Moll, 2003, The MDM2-p53 interaction, Molecular cancer research: MCR, 1, 1001
  53. SM Wuerzberger-Davis, 2007, NF-kappaB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage, Oncogene, 26, 641, 10.1038/sj.onc.1209815 · DOI
  54. Y Yang, 2011, A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage, Molecular and cellular biology, 31, 2774, 10.1128/MCB.01139-10 · DOI · Paper page
  55. ZH Wu, 2010, ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress, Molecular cell, 40, 75, 10.1016/j.molcel.2010.09.010 · DOI · Paper page
  56. L Ling, 1998, NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176, Proceedings of the National Academy of Sciences of the United States of America, 95, 3792, 10.1073/pnas.95.7.3792 · DOI · Paper page
  57. SC Sun, 1993, NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway, Science, 259, 1912, 10.1126/science.8096091 · DOI · Paper page
  58. E Zandi, 1997, The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation, Cell, 91, 243, 10.1016/S0092-8674(00)80406-7 · DOI · Paper page
  59. T Kawagoe, 2008, Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2, Nature immunology, 9, 684, 10.1038/ni.1606 · DOI · Paper page
  60. S Li, 2002, IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase, Proceedings of the National Academy of Sciences of the United States of America, 99, 5567, 10.1073/pnas.082100399 · DOI · Paper page
  61. H Wesche, 1997, MyD88: an adapter that recruits IRAK to the IL-1 receptor complex, Immunity, 7, 837, 10.1016/S1074-7613(00)80402-1 · DOI · Paper page
  62. K Yamasaki, 1988, Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor, Science, 241, 825, 10.1126/science.3136546 · DOI · Paper page
  63. J Yao, 2007, Interleukin-1 (IL-1)-induced TAK1-dependent Versus MEKK3-dependent NFkappaB activation pathways bifurcate at IL-1 receptor-associated kinase modification, The Journal of biological chemistry, 282, 6075, 10.1074/jbc.M609039200 · DOI
  64. A Kanayama, 2004, TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains, Molecular cell, 15, 535, 10.1016/j.molcel.2004.08.008 · DOI · Paper page
  65. J Ninomiya-Tsuji, 1999, The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway, Nature, 398, 252, 10.1038/18465 · DOI · Paper page
  66. C Wang, 2001, TAK1 is a ubiquitin-dependent kinase of MKK and IKK, Nature, 412, 346, 10.1038/35085597 · DOI · Paper page
  67. DR Hammaker, 2004, Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis, Journal of immunology, 172, 1612, 10.4049/jimmunol.172.3.1612 · DOI
  68. A Finch, 1997, Selective activation of JNK/SAPK by interleukin-1 in rabbit liver is mediated by MKK7, FEBS letters, 418, 144, 10.1016/S0014-5793(97)01364-1 · DOI
  69. C Tournier, 2001, MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines, Genes & development, 15, 1419, 10.1101/gad.888501 · DOI · Paper page
  70. M Kristiansen, 2010, Mkp1 is a c-Jun target gene that antagonizes JNK-dependent apoptosis in sympathetic neurons. The Journal of neuroscience: the official journal of the, Society for Neuroscience, 30, 10820
  71. T Inoue, 2005, Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes, Journal of immunology, 174, 4301, 10.4049/jimmunol.174.7.4301 · DOI
  72. AK Kiemer, 2002, Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability, Circulation research, 90, 874, 10.1161/01.RES.0000017068.58856.F3 · DOI · Paper page
  73. H van Dam, 1995, ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents, The EMBO journal, 14, 1798, 10.1002/j.1460-2075.1995.tb07168.x · DOI · Paper page
  74. R Wadgaonkar, 2004, Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells, American journal of respiratory cell and molecular biology, 31, 423, 10.1165/rcmb.2003-0384OC · DOI
  75. A Minden, 1994, c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases, Molecular and cellular biology, 14, 6683, 10.1128/MCB.14.10.6683 · DOI · Paper page
  76. BJ Pulverer, 1991, Phosphorylation of c-jun mediated by MAP kinases, Nature, 353, 670, 10.1038/353670a0 · DOI · Paper page
  77. M Hanlon, 2000, C/EBP beta and Elk-1 synergistically transactivate the c-fos serum response element, BMC cell biology, 1, 2, 10.1186/1471-2121-1-2 · DOI
  78. AL Silvers, 2003, The role of JNK and p38 MAPK activities in UVA-induced signaling pathways leading to AP-1 activation and c-Fos expression, Neoplasia, 5, 319, 10.1016/S1476-5586(03)80025-8 · DOI · Paper page
  79. GJ Babu, 2000, Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy, Journal of molecular and cellular cardiology, 32, 1447, 10.1006/jmcc.2000.1185 · DOI
  80. M Cavigelli, 1995, Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation, The EMBO journal, 14, 5957, 10.1002/j.1460-2075.1995.tb00284.x · DOI · Paper page
  81. E Yang, 2003, Independent and cooperative activation of chromosomal c-fos promoter by STAT3, The Journal of biological chemistry, 278, 15794, 10.1074/jbc.M213073200 · DOI · Paper page
  82. P Angel, 1991, The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation, Biochimica et biophysica acta, 1072, 129
  83. C Casals-Casas, 2009, CREB and AP-1 activation regulates MKP-1 induction by LPS or M-CSF and their kinetics correlate with macrophage activation versus proliferation, European journal of immunology, 39, 1902, 10.1002/eji.200839037 · DOI · Paper page
  84. E Sanchez-Tillo, 2007, JNK1 Is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation, The Journal of biological chemistry, 282, 12566, 10.1074/jbc.M609662200 · DOI · Paper page
  85. HB Kang, 2007, Enhancement of NF-kappaB expression and activity upon differentiation of human embryonic stem cell line SNUhES3, Stem cells and development, 16, 615, 10.1089/scd.2007.0014 · DOI
  86. C Kunsch, 1993, NF-kappa B subunit-specific regulation of the interleukin-8 promoter, Molecular and cellular biology, 13, 6137, 10.1128/MCB.13.10.6137 · DOI · Paper page
  87. L Neff, 2003, ERK 1/2- and JNKs-dependent synthesis of interleukins 6 and 8 by fibroblast-like synoviocytes stimulated with protein I/II, a modulin from oral streptococci, requires focal adhesion kinase, The Journal of biological chemistry, 278, 27721, 10.1074/jbc.M212065200 · DOI
  88. L Neff, 2001, NF-kappaB and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci, Cellular microbiology, 3, 703, 10.1046/j.1462-5822.2001.00148.x · DOI
  89. S Akira, 1990, A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family, The EMBO journal, 9, 1897, 10.1002/j.1460-2075.1990.tb08316.x · DOI · Paper page
  90. M Murakami, 1993, IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase, Science, 260, 1808, 10.1126/science.8511589 · DOI · Paper page
  91. DA Harrison, 2012, The Jak/STAT pathway, Cold Spring Harbor perspectives in biology, 4, 10.1101/cshperspect.a011205 · DOI · Paper page
  92. C Blanco-Aparicio, 2007, PTEN, more than the AKT pathway, Carcinogenesis, 28, 1379, 10.1093/carcin/bgm052 · DOI · Paper page
  93. ES Kandel, 1999, The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB, Experimental cell research, 253, 210, 10.1006/excr.1999.4690 · DOI · Paper page
  94. V Giordano, 1997, Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase, Journal of immunology, 158, 4097, 10.4049/jimmunol.158.9.4097 · DOI
  95. H Liu, 2013, ERK differentially regulates Th17- and Treg-cell development and contributes to the pathogenesis of colitis, European journal of immunology, 43, 1716, 10.1002/eji.201242889 · DOI
  96. FH Cruzalegui, 1999, ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry, Oncogene, 18, 7948, 10.1038/sj.onc.1203362 · DOI · Paper page
  97. K Yokogami, 2000, Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR, Current biology: CB, 10, 47, 10.1016/S0960-9822(99)00268-7 · DOI · Paper page
  98. JJ Schuringa, 2001, c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE), Cytokine, 14, 78, 10.1006/cyto.2001.0856 · DOI

Cited by

See all 75

Metadata

Authors
Meyer, P., Maity, P., Burkovski, A., Schwab, J., Müssel, C., Singh, K., Ferreira, F. F., Krug, L., Maier, H. J., Wlaschek, M., Wirth, T., Kestler, H. A., & Scharffetter-Kochanek, K.
Venue
PLOS Computational Biology
Published
2017-12-04
Volume
13
Issue
12
Pages
e1005741
ISSN
  • 1553-734X (ISSN-L)
  • 1553-7358
OpenAlex
W2774770284
Cited by
75
References
32
FWCI
3.43
Type
journal article
Language
en
Open access
gold
Funders
  • Deutsche Forschungsgemeinschaft (SCHA411/15‐2, GRK 1789, SFB 1074 project Z1)
  • Ministerium für Wissenschaft, Forschung und Kultur (FKZ0315894A SyStaR, e:Med, SYMBOL-HF, ID 01ZX1407A)
  • Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (CRC 1149)
  • European Research Council, FP7 (602783)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.